UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Ecdysteroid metabolism in mammals: The fate of ingested 20-hydroxyecdysone in mice and rats

The Journal of steroid biochemistry and molecular biology, 2021-09, Vol.212, p.105896, Article 105896

2021

Volltextzugriff (PDF)

Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial

Trials, 2021-01, Vol.22 (1), p.42-42, Article 42

2021

Volltextzugriff (PDF)

Anti-tumor effect and mechanisms of concurrent targeting EGFR and metabolism in sarcoma cell lines

European journal of cancer (1990), 2016-12, Vol.69, p.S37-S38

2016

Volltextzugriff (PDF)

Involvement of peroxisome proliferator activator receptors in the photoprotective activity of the di‐apo‐carotenoid norbixin on RPE cells

Acta ophthalmologica (Oxford, England), 2017-09, Vol.95 (S259), p.n/a

2017

Volltextzugriff (PDF)

SMA - TREATMENT

Neuromuscular disorders : NMD, 2021-10, Vol.31, p.S131

2021

Volltextzugriff (PDF)

SMA - TREATMENT: EP.268 In vivo effects of Sarconeos (API BIO101) on a mouse model of severe spinal muscular atrophy

Neuromuscular disorders : NMD, 2021-10, Vol.31, p.S131-S131

2021

Volltextzugriff (PDF)

FP.10 Combination of BIO101 with antisense oligonucleotide therapy demonstrates synergistic beneficial effects in severe SMA-like mice

Neuromuscular disorders : NMD, 2022-10, Vol.32, p.S58

2022

Volltextzugriff (PDF)

Arsenical-based cancer drugs

Cancer treatment reviews, 2007-10, Vol.33 (6), p.542-564

2007

Volltextzugriff (PDF)

EP.87MYODA clinical program: composite score for assessing the efficacy of BIO101 (MAS activator) in ambulatory and non-ambulatory Duchenne boys

Neuromuscular disorders : NMD, 2019-10, Vol.29, p.S178-S178

2019

Volltextzugriff (PDF)

P.370BIO101 demonstrates combined beneficial effects on muscle and motor neurons in a mouse model of severe spinal muscular atrophy

Neuromuscular disorders : NMD, 2019-10, Vol.29, p.S189-S189

2019

Volltextzugriff (PDF)

P.149The MYODA operational seamless clinical trial design phase I to III: a new approach for rare diseases to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of BIO101 (MAS activator) in paediatric patients with a genetically confirmed diagnosis of Duchenne muscular dystrophy

Neuromuscular disorders : NMD, 2019-10, Vol.29, p.S92-S92

2019

Volltextzugriff (PDF)

A refinement and an exact equality condition for the basic inequality of f-divergences

Filomat, 2018, Vol.32 (12), p.4263-4273

2018

Volltextzugriff (PDF)

DMD TREATMENT: ANIMAL MODELS: P.206Effects of sarconeos (API BIO101) on in vivo and in vitro models of Duchenne muscular dystrophy

Neuromuscular disorders : NMD, 2018-10, Vol.28, p.S95-S95

2018

Volltextzugriff (PDF)

DMD TREATMENT: ANIMAL MODELS

Neuromuscular disorders : NMD, 2018-10, Vol.28, p.S95

2018

Volltextzugriff (PDF)

93 - Anti-tumor effect and mechanisms of concurrent targeting EGFR and metabolism in sarcoma cell lines

European journal of cancer (1990), 2016-12, Vol.69, p.S37-S38

2016

Volltextzugriff (PDF)

P.311BIO101 demonstrates combined beneficial effects on skeletal muscle and respiratory functions in a mouse model of Duchenne muscular dystrophy

Neuromuscular disorders : NMD, 2019-10, Vol.29, p.S158-S158

2019

Volltextzugriff (PDF)

P08.22 Targeting glioblastoma mitochondrial metabolism to inhibit cell proliferation & tumor growth

Neuro-oncology (Charlottesville, Va.), 2017-05, Vol.19 (suppl_3), p.iii59-iii59

2017

Volltextzugriff (PDF)

ET-56 SENSITIZATION OF GLIOBLASTOMA CELLS TO IRRADIATION BY MODULATING THE GLUCOSE METABOLISM

Neuro-oncology (Charlottesville, Va.), 2014-11, Vol.16 (suppl 5), p.v91-v91

2014

Volltextzugriff (PDF)

A peptide trivalent arsenical inhibits tumor angiogenesis by perturbing mitochondrial function in angiogenic endothelial cells

Cancer cell, 2003-05, Vol.3 (5), p.497-509

2003

Volltextzugriff (PDF)

DD-04 PENAO: A POTENT MITOCHONDRIAL TARGETED INHIBITOR FOR GLIOBLASTOMA

Neuro-oncology (Charlottesville, Va.), 2014-11, Vol.16 (suppl 5), p.v60-v61

2014

Volltextzugriff (PDF)

Functional characterization of cystic fibrosis transmembrane conductance regulator (CFTR) in apical membranes purified from bovine tracheal epithelium

The Journal of biological chemistry, 1994-03, Vol.269 (10), p.7801-7806

1994

Volltextzugriff (PDF)

Synthesis and antiproliferative activity of O-silylated nucleoside triazene N-oxide derivatives

Carbohydrate letters, 2000, Vol.4 (1), p.5

2000

Volltextzugriff (PDF)

Mechanism of Selectivity of an Angiogenesis Inhibitor From Screening a Genome-Wide Set of Saccharomyces cerevisiae Deletion Strains

JNCI : Journal of the National Cancer Institute, 2005-10, Vol.97 (20), p.1539-1547

2005

Volltextzugriff (PDF)

Para to Ortho repositioning of the arsenical moiety of the angiogenesis inhibitor 4-(N-(S-glutathionylacetyl)amino) phenylarsenoxide results in a markedly increased cellular accumulation and antiproliferative activity

Cancer research (Chicago, Ill.), 2005-12, Vol.65 (24), p.11729-11734

2005

Volltextzugriff (PDF)

Alterations of ionic membrane permeabilities in multidrug-resistant neuroblastoma x glioma hybrid cells

Journal of experimental biology, 1998-01, Vol.201 (Pt 1), p.21-31

1998

Volltextzugriff (PDF)

1 – 25 von 50

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(45)
Mit Volltextzugriff
(48)

Publikationsform

Artikel
(49)
Tagungsberichte
(1)

Sprache

Englisch
(49)
Französisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Ecdysteroid metabolism in mammals: The fate of ingested 20-hydroxyecdysone in mice and rats

Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial

Anti-tumor effect and mechanisms of concurrent targeting EGFR and metabolism in sarcoma cell lines

Involvement of peroxisome proliferator activator receptors in the photoprotective activity of the di‐apo‐carotenoid norbixin on RPE cells

SMA - TREATMENT

SMA - TREATMENT: EP.268 In vivo effects of Sarconeos (API BIO101) on a mouse model of severe spinal muscular atrophy

FP.10 Combination of BIO101 with antisense oligonucleotide therapy demonstrates synergistic beneficial effects in severe SMA-like mice

Arsenical-based cancer drugs

EP.87MYODA clinical program: composite score for assessing the efficacy of BIO101 (MAS activator) in ambulatory and non-ambulatory Duchenne boys

P.370BIO101 demonstrates combined beneficial effects on muscle and motor neurons in a mouse model of severe spinal muscular atrophy

P.149The MYODA operational seamless clinical trial design phase I to III: a new approach for rare diseases to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of BIO101 (MAS activator) in paediatric patients with a genetically confirmed diagnosis of Duchenne muscular dystrophy

A refinement and an exact equality condition for the basic inequality of f-divergences

DMD TREATMENT: ANIMAL MODELS: P.206Effects of sarconeos (API BIO101) on in vivo and in vitro models of Duchenne muscular dystrophy

DMD TREATMENT: ANIMAL MODELS

93 - Anti-tumor effect and mechanisms of concurrent targeting EGFR and metabolism in sarcoma cell lines

P.311BIO101 demonstrates combined beneficial effects on skeletal muscle and respiratory functions in a mouse model of Duchenne muscular dystrophy

P08.22 Targeting glioblastoma mitochondrial metabolism to inhibit cell proliferation & tumor growth

ET-56 SENSITIZATION OF GLIOBLASTOMA CELLS TO IRRADIATION BY MODULATING THE GLUCOSE METABOLISM

A peptide trivalent arsenical inhibits tumor angiogenesis by perturbing mitochondrial function in angiogenic endothelial cells

DD-04 PENAO: A POTENT MITOCHONDRIAL TARGETED INHIBITOR FOR GLIOBLASTOMA

Functional characterization of cystic fibrosis transmembrane conductance regulator (CFTR) in apical membranes purified from bovine tracheal epithelium

Synthesis and antiproliferative activity of O-silylated nucleoside triazene N-oxide derivatives

Mechanism of Selectivity of an Angiogenesis Inhibitor From Screening a Genome-Wide Set of Saccharomyces cerevisiae Deletion Strains

Para to Ortho repositioning of the arsenical moiety of the angiogenesis inhibitor 4-(N-(S-glutathionylacetyl)amino) phenylarsenoxide results in a markedly increased cellular accumulation and antiproliferative activity

Alterations of ionic membrane permeabilities in multidrug-resistant neuroblastoma x glioma hybrid cells

Suchergebnisse filtern